TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Position Reduced by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. decreased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 30.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 30,553 shares of the biopharmaceutical company’s stock after selling 13,457 shares during the quarter. E Fund Management Co. Ltd.’s holdings in TG Therapeutics were worth $522,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new position in TG Therapeutics in the third quarter valued at about $1,219,000. Hussman Strategic Advisors Inc. acquired a new stake in TG Therapeutics in the third quarter valued at approximately $439,000. Rhenman & Partners Asset Management AB grew its position in TG Therapeutics by 190.9% in the third quarter. Rhenman & Partners Asset Management AB now owns 160,000 shares of the biopharmaceutical company’s stock worth $1,338,000 after acquiring an additional 105,000 shares in the last quarter. Rafferty Asset Management LLC increased its stake in shares of TG Therapeutics by 183.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 554,309 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter valued at $511,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

TG Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, reaching $17.12. The company had a trading volume of 4,229,547 shares, compared to its average volume of 4,335,392. The company has a 50 day moving average of $15.37 and a 200-day moving average of $14.68. TG Therapeutics, Inc. has a 52 week low of $6.46 and a 52 week high of $35.22. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of 74.43 and a beta of 2.33.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The firm had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. During the same period last year, the business earned ($0.28) earnings per share. The firm’s quarterly revenue was up 713.5% compared to the same quarter last year. On average, sell-side analysts expect that TG Therapeutics, Inc. will post -0.11 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. LADENBURG THALM/SH SH raised their target price on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. HC Wainwright upped their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, B. Riley lifted their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.